Previous 10 | Next 10 |
Arvinas announced decent data from ARV-110 in February. The market may have expected more. I will continue to hold. For further details see: Arvinas: Still Holding, Just Not Buying More
Even as macro concerns drove the major averages lower again in Monday's intraday action, earnings news remained a key catalyst for a handful of individual stocks. That list included Galaxy Digital (OTCPK:BRPHF), which lost more than a fifth of its value after the meltdown in the crypto market...
Arvinas (NASDAQ:ARVN -17.0%) stock falls after Wedbush downgraded rating to neutral from outperform and lowered PT to $48 from $98. Wedbush said it sees increased development challenges to breast cancer treatment, ARV-471, in light of recent study failures for oral SERDs amcenestrant (Sanofi)...
GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration PR Newswire SOMERVILLE, Mass. , May 9, 2022 /PRNewswire/ -- GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical comp...
Arvinas press release (NASDAQ:ARVN): Q1 GAAP EPS of -$1.20 misses by $0.28. Revenue of $24.2M (+336.8% Y/Y) misses by $1.31M. “It has been a very productive first quarter for Arvinas, as we prepare to initiate three planned pivotal clinical studies in the second half of 2022 for our tw...
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate u...
NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Bank of America Securities ...
Arvinas press release (NASDAQ:ARVN): Q4 GAAP EPS of -$1.00 misses by $0.21. Revenue of $26.3M (+1095.5% Y/Y) beats by $11.22M. For further details see: Arvinas GAAP EPS of -$1.00 misses by $0.21, revenue of $26.3M beats by $11.22M
NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and pro...
– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA 50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a mole...
News, Short Squeeze, Breakout and More Instantly...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the Biennial International LRRK2 Meeting high...